S&P 500   3,959.73 (-3.16%)
DOW   31,767.35 (-2.72%)
QQQ   295.35 (-3.53%)
AAPL   143.60 (-3.78%)
MSFT   257.72 (-3.41%)
FB   196.24 (-3.15%)
GOOGL   2,270.59 (-2.53%)
AMZN   2,190.61 (-5.06%)
TSLA   722.03 (-5.20%)
NVDA   173.33 (-4.64%)
BABA   88.88 (-3.38%)
NIO   16.09 (-3.25%)
AMD   98.41 (-3.96%)
CGC   5.76 (-2.21%)
MU   71.58 (-3.89%)
T   20.36 (-1.02%)
GE   75.75 (-0.85%)
F   12.98 (-4.07%)
DIS   105.99 (-2.44%)
AMC   13.17 (+2.09%)
PFE   50.59 (-1.46%)
PYPL   78.42 (-1.67%)
NFLX   181.40 (-4.81%)
S&P 500   3,959.73 (-3.16%)
DOW   31,767.35 (-2.72%)
QQQ   295.35 (-3.53%)
AAPL   143.60 (-3.78%)
MSFT   257.72 (-3.41%)
FB   196.24 (-3.15%)
GOOGL   2,270.59 (-2.53%)
AMZN   2,190.61 (-5.06%)
TSLA   722.03 (-5.20%)
NVDA   173.33 (-4.64%)
BABA   88.88 (-3.38%)
NIO   16.09 (-3.25%)
AMD   98.41 (-3.96%)
CGC   5.76 (-2.21%)
MU   71.58 (-3.89%)
T   20.36 (-1.02%)
GE   75.75 (-0.85%)
F   12.98 (-4.07%)
DIS   105.99 (-2.44%)
AMC   13.17 (+2.09%)
PFE   50.59 (-1.46%)
PYPL   78.42 (-1.67%)
NFLX   181.40 (-4.81%)
S&P 500   3,959.73 (-3.16%)
DOW   31,767.35 (-2.72%)
QQQ   295.35 (-3.53%)
AAPL   143.60 (-3.78%)
MSFT   257.72 (-3.41%)
FB   196.24 (-3.15%)
GOOGL   2,270.59 (-2.53%)
AMZN   2,190.61 (-5.06%)
TSLA   722.03 (-5.20%)
NVDA   173.33 (-4.64%)
BABA   88.88 (-3.38%)
NIO   16.09 (-3.25%)
AMD   98.41 (-3.96%)
CGC   5.76 (-2.21%)
MU   71.58 (-3.89%)
T   20.36 (-1.02%)
GE   75.75 (-0.85%)
F   12.98 (-4.07%)
DIS   105.99 (-2.44%)
AMC   13.17 (+2.09%)
PFE   50.59 (-1.46%)
PYPL   78.42 (-1.67%)
NFLX   181.40 (-4.81%)
S&P 500   3,959.73 (-3.16%)
DOW   31,767.35 (-2.72%)
QQQ   295.35 (-3.53%)
AAPL   143.60 (-3.78%)
MSFT   257.72 (-3.41%)
FB   196.24 (-3.15%)
GOOGL   2,270.59 (-2.53%)
AMZN   2,190.61 (-5.06%)
TSLA   722.03 (-5.20%)
NVDA   173.33 (-4.64%)
BABA   88.88 (-3.38%)
NIO   16.09 (-3.25%)
AMD   98.41 (-3.96%)
CGC   5.76 (-2.21%)
MU   71.58 (-3.89%)
T   20.36 (-1.02%)
GE   75.75 (-0.85%)
F   12.98 (-4.07%)
DIS   105.99 (-2.44%)
AMC   13.17 (+2.09%)
PFE   50.59 (-1.46%)
PYPL   78.42 (-1.67%)
NFLX   181.40 (-4.81%)
NASDAQ:ENTA

Enanta Pharmaceuticals Short Interest Ratio and Short Volume

$46.97
-2.06 (-4.20%)
(As of 05/18/2022 12:55 PM ET)
Add
Compare
Today's Range
$46.02
$47.95
50-Day Range
$48.77
$76.93
52-Week Range
$40.37
$102.00
Volume
11,014 shs
Average Volume
217,160 shs
Market Capitalization
$972.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.64

Enanta Pharmaceuticals (NASDAQ:ENTA) Short Interest Data

Current Short Volume
1,210,000 shares
Previous Short Volume
1,110,000 shares
Change Vs. Previous Month
+9.01%
Dollar Volume Sold Short
$77.92 million
Short Interest Ratio / Days to Cover
5.6
Last Record Date
April, 30 2022
Outstanding Shares
20,710,000 shares
Float Size
19,240,000 shares
Short Percent of Float
6.29%
Today's Trading Volume
11,014 shares
Average Trading Volume
217,160 shares
Today's Volume Vs. Average
-94.93%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Enanta Pharmaceuticals ?

Sign up to receive the latest short interest report for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time


Enanta Pharmaceuticals (NASDAQ:ENTA) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/30/20221,210,000 shares $77.92 million +9.0%6.3%5.6 $64.40
4/15/20221,110,000 shares $82.42 million -5.9%5.8%5.2 $74.25
3/31/20221,180,000 shares $83.99 million +9.3%6.1%5.4 $71.18
3/15/20221,080,000 shares $70.87 million +21.9%5.6%5.1 $65.62
2/28/2022886,300 shares $62.41 million +13.7%4.6%4 $70.42
2/15/2022779,800 shares $48.51 million -16.5%4.1%3.5 $62.21
1/31/2022933,700 shares $55.48 million +28.6%5.2%4.3 $59.42
1/15/2022726,100 shares $43.57 million +4.0%N/A0 $60.00
12/31/2021697,900 shares $52.19 million -2.4%3.9%3.5 $74.78
12/15/2021715,300 shares $52.22 million +5.4%4.0%3.6 $73.00
11/30/2021678,900 shares $59.93 million -0.3%3.8%3.7 $88.28
11/15/2021681,000 shares $61.21 million -36.9%3.8%4 $89.88
10/29/20211,080,000 shares $92.72 million -32.1%6.1%6.7 $85.85
10/15/20211,590,000 shares $113.64 million -9.7%8.9%10.8 $71.47
9/30/20211,760,000 shares $99.99 million -2.8%9.9%11.8 $56.81
9/15/20211,810,000 shares $106.16 million -7.2%10.1%11.7 $58.65
8/31/20211,950,000 shares $111.54 million -8.9%10.9%12 $57.20
8/13/20212,140,000 shares $100.90 million +4.9%12.0%13.8 $47.15
7/30/20212,040,000 shares $86.19 million +9.1%11.4%13.8 $42.25
7/15/20211,870,000 shares $78.73 million +7.5%10.5%13.5 $42.10
6/30/20211,740,000 shares $76.58 million -7.0%9.8%13.4 $44.01
6/15/20211,870,000 shares $89.57 million -1.6%10.5%15.6 $47.90
5/28/20211,900,000 shares $92.45 million -4.0%10.6%16.9 $48.66
5/14/20211,980,000 shares $99.59 million -2.5%11.1%15.3 $50.30
4/30/20212,030,000 shares $104.24 million -5.1%11.4%14.8 $51.35













Enanta Pharmaceuticals (NASDAQ:ENTA) Short Interest Frequently Asked Questions

What is Enanta Pharmaceuticals' current short interest?

Short interest is the volume of Enanta Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 1,210,000 shares of ENTA short. 6.29% of Enanta Pharmaceuticals' shares are currently sold short. Learn More on Enanta Pharmaceuticals' current short interest.

What is a good short interest ratio for Enanta Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Enanta Pharmaceuticals currently has a short interest ratio of 6.0. Learn More on Enanta Pharmaceuticals's short interest ratio.

Which institutional investors are shorting Enanta Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Enanta Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Enanta Pharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.29% of Enanta Pharmaceuticals' floating shares are currently sold short.

Is Enanta Pharmaceuticals' short interest increasing or decreasing?

Enanta Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,210,000 shares, an increase of 9.0% from the previous total of 1,110,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Enanta Pharmaceuticals' float size?

Enanta Pharmaceuticals currently has issued a total of 20,710,000 shares. Some of Enanta Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Enanta Pharmaceuticals currently has a public float of 19,240,000 shares.

How does Enanta Pharmaceuticals' short interest compare to its competitors?

6.29% of Enanta Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Enanta Pharmaceuticals: Bausch Health Companies Inc. (4.19%), Galapagos NV (0.98%), Arrowhead Pharmaceuticals, Inc. (4.03%), Cerevel Therapeutics Holdings, Inc. (5.17%), Ultragenyx Pharmaceutical Inc. (4.76%), Zai Lab Limited (0.00%), Cytokinetics, Incorporated (0.00%), Blueprint Medicines Co. (6.32%), CureVac (14.09%), and Mirati Therapeutics, Inc. (8.19%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Palo Alto Networks, Inc. ($4.31 billion), Charter Communications, Inc. ($3.24 billion), Lucid Group, Inc. ($2.25 billion), HP Inc. ($2.22 billion), GameStop Corp. ($1.69 billion), Carnival Co. & plc ($1.66 billion), Snap Inc. ($1.64 billion), Wayfair Inc. ($1.63 billion), Rivian Automotive, Inc. ($1.60 billion), and Upstart Holdings, Inc. ($1.53 billion). View all of the most shorted stocks.

What does it mean to sell short Enanta Pharmaceuticals stock?

Short selling ENTA is an investing strategy that aims to generate trading profit from Enanta Pharmaceuticals as its price is falling. Enanta Pharmaceuticals' stock is trading down $2.06 today. To short Enanta Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Enanta Pharmaceuticals will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Enanta Pharmaceuticals?

A short squeeze for Enanta Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENTA, which in turn drives the price of the stock up even further.

How often is Enanta Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENTA, twice per month. The most recent reporting period available is April, 30 2022.



This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.